Krónikus limfoid leukémia (CLL): vizsgálatok itt: Spanyolország
43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA long-term follow-up study for patients treated with Galapagos CAR T cell therapies
- Where
- Barcelona
- Életkor
- 18 év and over
- People
- 309 worldwide
- Run by
- Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 - 3. fázisTaking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Barcelona, Girona, Madrid, Majadahonda, Marbella, Pamplona, Santander, Sevilla
- Életkor
- 18 év and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - 1. fázisFelfüggesztveDose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- Where
- Madrid, Pamplona
- Életkor
- 18 év and over
- People
- 85 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00 - 1. fázisTaking peopleStudy Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Barcelona
- Életkor
- 18 év and over
- People
- 54 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2022-501876-24-00 - 3. fázisBefejeződöttA Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
- Where
- Girona
- Életkor
- 18 év and over
- People
- 344 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06319456 · EU 2024-514084-26-00 - 2. fázisTaking peopleA multicenter, phase 2 randomized, open label study to evaluate the efficacy and security of zanubrutinib in combination with obinutuzumab in previously untreated patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (GELLC-10-ZANUBIO)
- Where
- Badalona, Barcelona, Córdoba, Las Palmas De Gran Canaria, Madrid, Málaga, Marbella, Oviedo, Salamanca, Santander, Sevilla, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 106
- Run by
- Pethema Fundacion
See details and how to join2023-504647-14-00 - 1. fázisTaking peopleA Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Where
- Barcelona, Madrid, Pamplona
- Életkor
- 18 év and over
- People
- 22 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-514152-32-00 - 1. fázisTaking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Barcelona, Gijón, Madrid
- Életkor
- 18 év and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - 1/2. fázisTaking peoplePhase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Murcia, Salamanca, Santander, Sevilla, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 62
- Run by
- Idp Discovery Pharma S.L.
See details and how to join2024-519194-19-00 - 2. fázisTaking peopleZanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga, Marbella, Oviedo, Palma de Mallorca, Pamplona, Salamanca, Santander, Seville, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 106
- Run by
- PETHEMA Foundation
See details and how to joinNCT06544785 - 3. fázisTaking peopleGlobal Trial in APG2575 for Patients With CLL/SLL
- Where
- Barcelona, Madrid, Palma, Santander, Valencia
- Életkor
- 18 év to 99 év
- People
- 400 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00 - 2. fázisTaking peopleA Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 108 worldwide
- Run by
- Curis, Inc.
See details and how to joinNCT07271667 · EU 2025-523600-68-00 - 3. fázisFut, nem toborozA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Where
- Madrid, Majadahonda, Pamplona, Santiago de Compostela, Sevilla
- Életkor
- 18 év and over
- People
- 170 worldwide
- Run by
- AbbVie
See details and how to joinNCT06428019 · EU 2024-512147-23-00 - 1. fázisTaking peopleStudy of SGR-1505 in Mature B-Cell Neoplasms
- Where
- L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
- Életkor
- 18 év and over
- People
- 98 worldwide
- Run by
- Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00 - 2. fázisTaking peopleStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Where
- Madrid
- Életkor
- 18 év and over
- People
- 75 worldwide
- Run by
- AbbVie
See details and how to joinNCT04895436 · EU 2023-504599-10-00 - 3. fázisTaking peopleA Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
- Where
- Albacete, Alicante, Badalona, Cáceres, Córdoba, Madrid, Sevilla, Terrassa, Valencia
- Életkor
- 70 év and over
- People
- 262 worldwide
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07082452 · EU 2025-521634-29-00 - 1. fázisTaking peopleCAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Where
- Madrid, Santander, Santiago de Compostela
- Életkor
- 18 év and over
- People
- 18 worldwide
- Run by
- Catapult Therapeutics
See details and how to joinNCT04704323 · EU 2024-516341-39-00 - 1/2. fázisTaking peopleA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
- Where
- Barcelona, Madrid, Murcia, Salamanca, Santander, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 37
- Run by
- IDP Discovery Pharma S.L.
See details and how to joinNCT05908409